louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00159367: The Use of Repetitive Magnetic Stimulation for Strength Training of the Quadriceps Muscle
Official title: The Use of Repetitive Magnetic Stimulation for Strength Training of the Quadriceps Muscle in Patients With Chronic Obstructive Pulmonary Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: Neuromuscular electrical stimulation
Lead sponsor: Imperial College London
Sponsor class: OTHER
Collaborators: name: Magstim Company, Whitland, Wales
First posted: 2005-09-12
Enrollment: 20
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: We intend to use repetitive magnetic stimulation to the quadriceps muscle to try to improve strength and improve the metabolic function of the muscle.

Detailed description: Quadriceps strength is reduced in COPD. Increasing quadriceps strength is one of the goals of pulmonary rehabilitation yet some patients with severe COPD are unable to exercise with sufficient intensity, due to breathlessness, to achieve a true training benefit.

Transcutaneous electrical stimulation of the femoral nerve has been shown to improve quadriceps muscle strength, muscle mass, and performance in patients with severe COPD. Magnetic stimulation may be preferred because it offers the opportunity to train the whole muscle and because it is painless. In this pilot study we are investigating whether repetitive magnetic stimulation camn increase the strength of the quadriceps muscle and whether it confers any change in structure or metabolism of the muscle itself.

Eligibility criteria: Inclusion Criteria:

Chronic Obstructive Pulmonary Disease

Exclusion Criteria:

Aspirin therapy Cardiac Pacemaker

-

Primary outcomes:
measure: Quadriceps Twitch force
Secondary outcomes:
measure: Quadriceps maximal voluntary contraction, Oxidative enzyme profile, fibre type distribution and capillarity of the muscle, quality of life questionnaires
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Royal Brompton Hospital
Study officials:
affiliation: Imperial College London
name: Michael I Polkey, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06862167: Desarda's Technique Versus Lichtenstein's Technique Hernia Repair in Management of Elective Non-Complicated Inguinal Hernia
Official title: Comparative Study Between Desarda's Technique Versus Lichtenstein's Technique Hernia Repair in Management of Elective Non-complicated Inguinal Hernia (Randomized Controlled Trial)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Desarda's Technique
Lichtenstein's Technique
Hernia Repair
Inguinal Hernia
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2025-03-06
Enrollment: 200
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to compare Desarda's technique and Lichtenstein's technique of hernia repair in managing elective, non-complicated inguinal hernia.

Detailed description: Mesh prosthesis was introduced to hernial surgery as a magic solution for any inguinal hernia, and it has significant advantages (Simplicity of the procedure, Mesh is cheap, and has a low recurrence rate). Still, mesh induces fibrosis that can lead to stiffness and foreign body sensation, which become a source of agony for the patient. Mesh infection is one of the serious complications that can lead to the removal of the mesh and long-term terms morbidity from Lichtenstein hernia repairs, such as Vas entrapment and Chronic groin pain.

Desarda technique requires no extensive dissection or only suturing; no mesh is needed, and it is easy to learn. It is still ferrated and determined the optimum procedure to treat an inguinal hernia. It is a straightforward operation that avoids the risks of mesh implantation, has a low recurrence rate, and can be done by non-consultant staff.

Eligibility criteria: Inclusion Criteria:

* Above 14 years of age.
* With reducible non-complicated inguinal or inguinoscrotal hernia; unilateral or bilateral

Exclusion Criteria:

* Obstructive uropathy or chronic obstructive pulmonary disease because they are contraindications to elective hernia surgery. They are associated with definite poor outcomes, such as high recurrence rates.
* Unfit patients for surgery
* Patients with strangulated hernia.
* Recurrent Hernias.
* Per operative finding of separated, thin, and/or weak external oblique aponeurosis

Primary outcomes:
measure: Incidence of postoperative complications
timeFrame: 1 year postoperatively
Secondary outcomes:
measure: Time till stop of postoperative analgesic
timeFrame: 30 days postoperatively
measure: Return to normal activity
timeFrame: 30 days postoperatively
measure: Incidence of recurrence
timeFrame: 1 year postoperatively
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Minia University
state: Minia
Study officials:
References:
Clinical trial NCT01716767: Acute Effect of Topical Menthol on Carpal Tunnel Syndrome
Official title: Acute Effect of Topical Menthol on Pain Symptoms in Slaughterhouse Workers With Symptoms of Carpal Tunnel Syndrome: Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Carpal Tunnel Syndrome
Keywords: Carpal tunnel syndrome
hand pain
wrist pain
arm pain
topical menthol
Lead sponsor: National Research Centre for the Working Environment, Denmark
Sponsor class: OTHER_GOV
Collaborators: name: Marquette University
First posted: 2012-10-30
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 67
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Topical menthol gels are classified 'topical analgesics' and are used to relieve pain of the musculoskeletal system. However, double-blind randomized controlled trials are lacking. Here the investigators examine - in a double-blind randomized controlled cross-over trial - the acute effect of topical menthol (Biofreeze) and placebo (gel with a menthol scent) on pain symptoms in slaughterhouse workers with symptoms of Carpal Tunnel Syndrome.


Eligibility criteria: Inclusion Criteria:

* positive Phalen test
* positive Tinel test
* nocturnal hand/wrist pain
* pain intensity of at least 4 in the hand/wrist
* the pain should have lasted at least 3 months

Exclusion Criteria:

* pregnancy
* life-threatening disease

Primary outcomes:
measure: Change in arm/hand pain intensity (scale 0-10) during work
timeFrame: change from before to after (average of 1,2 and 3 hours after) application of the gel
Secondary outcomes:
measure: GROC
timeFrame: 3 hours after application of the gel
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: National Research Centre for the Working Environment
Study officials:
affiliation: Professor
name: Lars L Andersen, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01114867: Fetal Penile Length and Corpus Cavernosum Length - Normal Measurement Via Ultrasound
Official title: Prospective Cross-sectional Study of Fetal Penis and Corpus Cavernosum Length
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Fetal Penis Length
Keywords: ultrasound
penis length
corpus cavernosum
length of fetal penis and fetal corpus cavernosum
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2010-05-03
Enrollment: 200
Sex: MALE
Minimum age (years): 14
Maximum age (years): 34
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Fetuses of healthy pregnant women

Brief summary: Hypothesis: Measurement of fetal penis length by ultrasound may be inaccurate when measured from the scrotum to the penile tip. we will provide normal values of penile length measured from the penile tip to the abdominal wall and measuring the corpus cavernosum length.


Eligibility criteria: Inclusion Criteria:

* pregnant women at 14th through 34th week gestation,
* routine ultrasound not preformed for anomalies at the genitourinary system,
* estimated fetal weight corresponds to gestational age.

Exclusion Criteria:

* women who's fetuses are suspected to be with fetal growth retardation,
* women who's fetuses are suspected to be with genitourinary anomaly.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tel-Aviv
country: Israel
facility: Ultrasound Unit in OBGYN, Soraski Medical Center
Study officials:
affiliation: Tel-Aviv, Soraski Medical Center
name: Yoseph Hartoov, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00005767: Dynamic Aspects of Amino Acid Metabolism
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Kidney Diseases
Keywords: Amino Acid Metabolism
Lead sponsor: National Center for Research Resources (NCRR)
Sponsor class: NIH
First posted: 2000-06-02
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: NATURAL_HISTORY
Time perspective: CROSS_SECTIONAL

Brief summary: This protocol seeks to define aspects of intestinal and hepatic uptake and metabolism of several amino acids. The major hypothesis to be tested is that the splanchic bed (intestine and liver) conserves essential amino acids and metabolites while synthesizing and metabolizing nonessential amino acids. The aims of the study include defining the relative roles of enteral and hepatic extraction/metabolism in the disposition of glutamate, alanine, methionine and other amino acids. Emphasis will also be placed on studies of the transamination of alpha-ketoisocaproic acid (KIC) to leucine since this reaction is of potential importance in the design of nutritional regimens for patients with renal disease.


Eligibility criteria: Inclusion Criteria:

* normal weight-for-height weight 50-80 kg
* normal physical activity
* no significant medical history
* healthy by medical exam and lab blood testing

Exclusion Criteria:

* subjects who exercise vigorously
* subjects who smoke

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Burlington
country: United States
facility: University of Vermont
state: Vermont
Study officials:
References:
Clinical trial NCT03957967: Acute Pain Assessment Using Facial Expression Analysis
Official title: Development of a Digital Solution for Acute Pain Assessment Using Automartized Facial Expression Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Pre and Post Operative Pain
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2019-05-21
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: any patient undergoing in our institution and accepting to participate

Brief summary: Managing pain, which affects 20-50% of the population, is a major issue in daily clinical practice. Evaluation of pain intensity is essential to adapt treatment but as it mainly relies on self-report, this assessment is difficult or impossible in non-communicating patients. In these cases, pain can only be evaluated by medical staff by the observation of pain-related characteristics like facial expression of pain (FEP). However, recognition of FEP is subjective, time-consuming and subject to multiple biases frequently leading to underestimation of pain and consequently under-treatment. Some of these biases could be solved by the use of facial recognition technology, allowing objective, automated and time-saving pain assessment. DEF-I aims to address technical issues and achieve the development of facial expression recognition digital tool able to evaluate severe acute pain in clinical practice, with high validity and utility by improving the quality of the images to be analyzed, by studying larger samples of patients, data and images, in order to correlate more efficiently the pain intensity felt by a patient with the expression of his face. The main objective of this study is to verify whether it is possible to quantitatively correlate the intensity of acute postoperative pain felt by a patient with his facial expression. The secondary objective is to define a reliable computer algorithm that qualitatively correlates the type of acute postoperative pain experienced by a patient with his facial expression.


Eligibility criteria: Inclusion Criteria:

* Any adult patient undergoing surgery in our institution during the study duration,
* able to express pain intensity on NRS

Exclusion Criteria:

* patient to be operated on in the area of the face or eye
* Patient with altered facial morphology related to a dressing, suture, wound, trauma or oedema on the face
* patient not compliant or unable to clearly express pain

Primary outcomes:
measure: measure of pain
timeFrame: t0=before surgery
measure: measure of pain
timeFrame: t1=after surgery
Secondary outcomes:
measure: facial expression
timeFrame: t0=before surgery
measure: facial expression
timeFrame: t1=after surgery
Other outcomes:
Locations:
city: Nice
country: France
facility: Hôpital Pasteur
Study officials:
References:
Clinical trial NCT05614167: Relationship Between Isometric Muscle Strength and Gross Motor Function in Children With Unilateral Cerebral Palsy
Official title: Relationship Between Isometric Muscle Strength and Gross Motor Function in Children With Unilateral Cerebral Palsy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hemiplegia
Cerebral Palsy
Keywords: Hemiplegia
Cerebral Palsy
muscle stength
gmfm
Lead sponsor: Badr University
Sponsor class: OTHER
First posted: 2022-11-14
Enrollment: 97
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Muscle weakness was found in children with CP, increasing with severity of gross motor function, approximately 50% of the predicted muscle strength was needed to be able to walk without aids.

Brief summary: Muscle strength can be defined as the ability of skeletal muscle to develop force for the purpose of providing stability and mobility within the musculoskeletal system, so that functional movement can take place.

Detailed description: Cerebral palsy describes a group of disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fatal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, cognition, communication, perception, and/or behaviour, and/or by a seizure disorder

The development and changes in motor function, both natural and with therapy, can be assessed using the Gross Motor Function Measure (GMFM) created for children with CP

Eligibility criteria: Inclusion Criteria:

1. Their age between 6 and 12 years old.
2. Grade 1and 2 according to the Modified Ashworth scale (RW and Smith, 1987).
3. They could walk with limitation or holding on according to GMFCS (level I, II) (Palisano et al., 1997).
4. They were able to understand and follow verbal instructions.

Exclusion Criteria:

1. Children with any visual or auditory problems.
2. Children with any surgical interference in the lower limb.
3. Children with any structural deformities in joints and bones of lower limbs.
4. Children with any special medications affecting muscle functions (anti-spastic drugs).
5. Children who suffer from other diseases or associated disorders that interfered with physical activity.

Primary outcomes:
measure: Gross motor function measure
timeFrame: 3 months
measure: Isometric muscle strength
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Badr University
Study officials:
affiliation: lecturer
name: Omnya samy, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04149067: Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain
Official title: Retrospective and Multicenter Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Sponsor class: OTHER
Collaborators: name: AstraZeneca
First posted: 2019-11-04
Enrollment: 1080
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients over 18 years old with stable DM2 with antihyperglycaemic therapy, being included in their treatment dapagliflozin or sitagliptin medication.

Brief summary: The aim of this study is to develop a retrospective, multicenter and observational study in Spain in real clinical practice to assess the employment of dapagliflozin and to compare its effectiveness and safety with the data of sitagliptin, a DPP4 inhibitor. This is a widely used molecule in Spain with a large safety profile. It was chosen as a comparator because of the number of patients treated and because it is a real alternative at the time of making a decision about the treatment.


Eligibility criteria: Inclusion Criteria:

1. Patients diagnosed with T2DM.
2. Age: 18-75 years.
3. Treatment with dapagliflozin or sitagliptin that started at least 6 months before the recruitment date.
4. The patient must have at least two follow-up visits. The basal initial visit, where all the relevant information is collected and a second follow-up visit.
5. The next information of the subjects should be available at the recruitment of the basal visit: Sex, age (years), date of diagnosis of T2DM, weight, height, systolic and diastolic blood pressure, body mass index (BMI: kg / m2), concomitant medication (antiHTA, statins, aspirin, etc.), glucose basal fasting (mg / dL), HbA1c (%) and estimated GFR by CKD-EPI (mL / min / 1.73m2).

5. The patient must sign the informed consent to participate in the study.

Exclusion Criteria:

1. Impediment of the patient to give him informed consent.
2. Patients diagnosed with Type 1 Diabetes.
3. Women with gestational diabetes.

Primary outcomes:
measure: 0.5% in Hb1Ac and 1.5 kg in body weight
timeFrame: 6 months +/- 3 months
Secondary outcomes:
measure: Evaluate the results due to the use of SGLT2i/DPP4i
timeFrame: 6 months +/- 3 months
measure: Evaluate the security of the treatment
timeFrame: 6 months +/- 3 months
Other outcomes:
Locations:
city: Sevilla
country: Spain
facility: Cristóbal Morales Portillo
state: Andalucía
Study officials:
affiliation: Hospital Universitario Virgen Macarena
name: Cristobal Morales Portillo
role: STUDY_DIRECTOR
References:
Clinical trial NCT01545167: The North American Pancreatitis Study
Official title: The North American Pancreatitis Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pancreatitis
Keywords: African Americans
pancreatitis
controls
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
First posted: 2012-03-06
Enrollment: 2980
Sex: ALL
Minimum age (years): 14
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: people with and without pancreatitis

Brief summary: This study will investigate several genes and other factors measured in the blood that may cause recurrent acute pancreatitis and chronic pancreatitis. No treatment is offered as part of this study. Subjects have one single visit to provide a blood sample for genetic testing and to answer a questionnaire. Subjects are not given results of genetic testing. The study is currently enrolling African American subjects and controls only.

Detailed description: This study seeks to enroll African American people with and without pancreatitis. There is only one study visit to obtain consent, a blood sample and complete a questionnaire. Subjects must be patients of a participating center; controls must present to a participating center for enrollment.

Eligibility criteria: Inclusion Criteria:

African American

pancreatitis patients who are at least 14 years of age with a diagnosis of acute or chronic pancreatitis

* controls who do not have pancreatitis and must be at least 18 years of age

Exclusion Criteria:

* unable or unwilling to sign informed consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh
state: Pennsylvania
Study officials:
References:
citation: Dunbar EK, Greer PJ, Amann ST, Alkaade S, Banks P, Brand R, Conwell DL, Forsmark CE, Gardner TB, Guda NM, Lewis MD, Machicado JD, Muniraj T, Papachristou GI, Romagnuolo J, Sandhu BS, Sherman S, Slivka A, Wilcox CM, Yadav D, Whitcomb DC; NAPS2 Consortium. Pain Experience in Pancreatitis: Strong Association of Genetic Risk Loci for Anxiety and PTSD in Patients With Severe, Constant, and Constant-Severe Pain. Am J Gastroenterol. 2021 Oct 1;116(10):2128-2136. doi: 10.14309/ajg.0000000000001366.
citation: Dunbar E, Greer PJ, Melhem N, Alkaade S, Amann ST, Brand R, Cote GA, Forsmark CE, Gardner TB, Gelrud A, Guda NM, LaRusch J, Lewis MD, Machicado JD, Muniraj T, Papachristou GI, Romagnuolo J, Sandhu BS, Sherman S, Wilcox CM, Singh VK, Yadav D, Whitcomb DC; NAPS2 study group. Constant-severe pain in chronic pancreatitis is associated with genetic loci for major depression in the NAPS2 cohort. J Gastroenterol. 2020 Oct;55(10):1000-1009. doi: 10.1007/s00535-020-01703-w. Epub 2020 Jul 17.
Clinical trial NCT01107067: Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism
Official title: Phase IV Study to Investigate the Effect of Testosterone Treatment on Paraoxonase Level in Male Patients With Hypogonadotrophic Hypogonadism
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypogonadism
Keywords: hypogonadism
paraoxonase
Hipogonadism
Lead sponsor: Gulhane School of Medicine
Sponsor class: OTHER
First posted: 2010-04-20
Enrollment: 32
Sex: MALE
Minimum age (years): 20
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: The purpose of this study is investigating the effect of testosterone treatment on paraoxonase level in male patients with hypogonadotrophic hypogonadism


Eligibility criteria: Inclusion Criteria:

* Volunteers patients with hypogonadism

Exclusion Criteria:

* Coronary heart disease
* Other pituitary/hypothalamic disorders or other non-hypogonadism diseases
* None was receiving vitamins, lipid-lowering drugs, or other medications known to interfere with PON1 activity, lipid profile, or gonadal function

Primary outcomes:
measure: paraoxonase level after testosterone treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Aydoğan AYDOĞDU
Study officials:
References: